Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07046663 | Long-term Assessment of Chlormethine Gel in Mycosis Fungoides(FIL_CLOR-CTCL) | not yet recruiting | — | 190 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07046182 | Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight | active not recruiting | Phase 4 | 34 | Zhengzhou UniversityOTHER | 1 | Jul 1, 2025 |
| clinicaltrials |
| NCT07032532 | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | not yet recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06550427 | Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing | recruiting | — | 200 | National Taiwan University HospitalOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | recruiting | Phase 2 | 57 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04668690 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | active not recruiting | Phase 3 | 193 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT01793168 | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford(CoRDS) | recruiting | — | 20,000 | Sanford HealthOTHER | 2 | May 29, 2025 | clinicaltrials |
| NCT06849401 | The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 15, 2025 | clinicaltrials |
| NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | recruiting | Phase 2 | 115 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06963632 | A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma(JOYCE) | not yet recruiting | — | 1,000 | Ruijin HospitalOTHER | 0 | May 9, 2025 | clinicaltrials |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | recruiting | Phase 2 | 59 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03964480 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | recruiting | — | 1,000 | Associazione Angela Serra per la ricerca sul cancroOTHER | 4 | May 6, 2025 | clinicaltrials |
| NCT06382844 | Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL | recruiting | — | 100 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06953739 | A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. | not yet recruiting | Phase 3 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | active not recruiting | Phase 1 | 151 | Corvus Pharmaceuticals, Inc.INDUSTRY | 4 | Apr 16, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE) | recruiting | Phase 1 | 24 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06863441 | The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma | not yet recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06151106 | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06361329 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | recruiting | Phase 3 | 81 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06824883 | Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma | recruiting | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT05958719 | Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06747299 | The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06741813 | Allo-HSCT vs ASCT in Adult T-LBL(TROPHY-NHL01) | not yet recruiting | N/A | 230 | Peking University People's HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06739265 | Golidocitinib Plus CHOP in Newly Diagnosed PTCL | recruiting | Phase 1 / Phase 2 | 68 | Peking Union Medical College HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05934513 | A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 95 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03385226 | A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)(PORT) | active not recruiting | Phase 2 | 46 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06701344 | Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients(GOAL) | not yet recruiting | Phase 2 | 7 | Ruijin HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06176027 | Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 52 | Navy General Hospital, BeijingOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05662540 | PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06651203 | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study(KISS01) | not yet recruiting | — | 460 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633354 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06598722 | BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. | recruiting | Phase 2 | 206 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06550336 | A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). | active not recruiting | Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 4, 2025source: clinicaltrials